Trust Company of Vermont’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$4.6M Sell
184,643
-32,076
-15% -$809K 0.19% 97
2025
Q3
$5.52M Sell
216,719
-29,372
-12% -$725K 0.24% 90
2025
Q2
$5.97M Sell
246,091
-36,394
-13% -$849K 0.28% 82
2025
Q1
$7.16M Sell
282,485
-41,031
-13% -$1.07M 0.36% 69
2024
Q4
$8.58M Sell
323,516
-84,607
-21% -$2.29M 0.42% 64
2024
Q3
$11.8M Buy
408,123
+6,243
+2% +$182K 0.59% 50
2024
Q2
$11.2M Buy
401,880
+14,554
+4% +$401K 0.61% 47
2024
Q1
$10.7M Buy
387,326
+67,617
+21% +$1.88M 0.6% 52
2023
Q4
$9.2M Sell
319,709
-49,871
-13% -$1.51M 0.61% 54
2023
Q3
$12.3M Buy
369,580
+29,546
+9% +$1.04M 0.83% 36
2023
Q2
$12.5M Buy
340,034
+32,254
+10% +$1.26M 0.81% 34
2023
Q1
$12.6M Buy
307,780
+13,841
+5% +$598K 0.88% 33
2022
Q4
$15.1M Buy
293,939
+7,887
+3% +$378K 1.1% 24
2022
Q3
$12.5M Buy
286,052
+2,589
+0.9% +$126K 0.99% 27
2022
Q2
$14.9M Sell
283,463
-10,043
-3% -$512K 1.14% 22
2022
Q1
$15.2M Sell
293,506
-12,263
-4% -$636K 1.03% 26
2021
Q4
$18.1M Buy
305,769
+15,800
+5% +$783K 1.14% 20
2021
Q3
$12.5M Sell
289,969
-4,716
-2% -$209K 0.89% 35
2021
Q2
$11.5M Buy
294,685
+12,429
+4% +$483K 0.8% 38
2021
Q1
$10.2M Buy
282,256
+10,557
+4% +$375K 0.77% 42
2020
Q4
$10M Buy
271,699
+3,562
+1% +$131K 0.8% 39
2020
Q3
$9.34M Buy
268,137
+14,108
+6% +$495K 0.85% 34
2020
Q2
$7.88M Sell
254,029
-48,686
-16% -$1.65M 0.78% 39
2020
Q1
$9.37M Buy
302,715
+13,358
+5% +$455K 0.88% 36
2019
Q4
$10.8M Buy
289,357
+7,434
+3% +$265K 0.81% 43
2019
Q3
$9.61M Sell
281,923
-6,184
-2% -$225K 0.77% 44
2019
Q2
$11.8M Buy
288,107
+1,375
+0.5% +$54.6K 0.98% 33
2019
Q1
$11.6M Buy
286,732
+851
+0.3% +$34.1K 0.99% 30
2018
Q4
$11.8M Sell
285,881
-4,271
-1% -$177K 1.14% 21
2018
Q3
$12.1M Sell
290,152
-7,809
-3% -$301K 1.02% 24
2018
Q2
$10.3M Buy
297,961
+14,182
+5% +$485K 0.92% 31
2018
Q1
$9.55M Sell
283,779
-1,936
-0.7% -$66.6K 0.9% 32
2017
Q4
$9.82M Buy
285,715
+16,952
+6% +$578K 0.91% 33
2017
Q3
$9.1M Buy
268,763
+2,313
+0.9% +$74.3K 0.9% 34
2017
Q2
$8.49M Buy
266,450
+7,377
+3% +$233K 0.87% 32
2017
Q1
$8.41M Buy
259,073
+2,406
+0.9% +$75.9K 0.91% 29
2016
Q4
$7.91M Buy
256,667
+3,036
+1% +$92.7K 0.91% 28
2016
Q3
$8.15M Buy
253,631
+15,384
+6% +$514K 1.02% 25
2016
Q2
$7.96M Buy
238,247
+10,984
+5% +$351K 1.06% 24
2016
Q1
$6.39M Sell
227,263
-308
-0.1% -$8.8K 0.89% 31
2015
Q4
$6.97M Buy
227,571
+1,208
+0.5% +$38K 1% 27
2015
Q3
$6.75M Buy
226,363
+2,789
+1% +$89.4K 1.05% 25
2015
Q2
$7.11M Buy
223,574
+1,345
+0.6% +$43.8K 1.03% 26
2015
Q1
$7.33M Sell
222,229
-4,244
-2% -$135K 1.07% 27
2014
Q4
$6.69M Buy
226,473
+3,493
+2% +$100K 0.98% 32
2014
Q3
$6.26M Buy
222,980
+16,309
+8% +$458K 0.95% 30
2014
Q2
$5.82M Buy
206,671
+2,647
+1% +$75.5K 0.9% 35
2014
Q1
$6.22M Buy
204,024
+9,051
+5% +$270K 1.02% 26
2013
Q4
$5.67M Sell
194,973
-1,086
-0.6% -$31.6K 0.95% 28
2013
Q3
$5.34M Sell
196,059
-38
-0% -$1.03K 0.98% 28
2013
Q2
$5.21M Buy
+196,097
New +$5.42M 1.02% 26

Other funds holding PFE

Trust Company of Vermont's PFE Position: Q4 2025 in Review

Trust Company of Vermont reduced its Pfizer (PFE) stake by 15% in Q4 2025, selling an estimated $809K and leaving 184,643 shares worth $4.6M. The position accounts for 0.19% of the portfolio, ranked #97.

Trust Company of Vermont first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $18.1M in Q4 2021. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Trust Company of Vermont held 184,643 shares of Pfizer worth $4.6M as of Q4 2025.
  • Trust Company of Vermont sold 32,076 Pfizer shares in Q4 2025, an estimated $809K.
  • Pfizer made up 0.19% of Trust Company of Vermont's portfolio in Q4 2025, its #97 holding.
  • Trust Company of Vermont first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
  • Trust Company of Vermont's Pfizer position peaked at $18.1M in Q4 2021.
  • 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.